The global fragment based drug discovery market involves screening of low molecular weight fragments that have the potential to bind to specific biological targets or receptors. Fragment based screening offers advantages such as low molecular weight hits that have attractive drug-like properties and provide opportunities for expansion to develop high-affinity leads. Recent advancements in integrated biophysical technologies have enabled researchers to discover previously unknown binding sites on biological targets, facilitating drug development against difficult targets.
The Global Fragment Based Drug Discovery Market is estimated to be valued at USD 1.21 Bn in 2024 and is expected to reach USD 2.60 Bn by 2031, growing at a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.
Key Takeaways
Key players operating in the global fragment based drug discovery market are Astex Pharmaceuticals, Alveus Pharmaceuticals Pvt. Ltd., Beactica AB, Crown Bioscience Inc., Emerald Cloud Lab LLC, Evotec AG, Kinetic Discovery Limited, Structure Based Design Inc., Sygnature Discovery.
The key opportunities in the market include expanding applications of Global Fragment Based Drug Discovery Market based screening to discover novel small molecule drugs against challenging targets, increasing collaborations between pharmaceutical companies and research organizations for accelerating drug discovery.
Advancements in biophysical techniques such as NMR, X-ray crystallography, and SPR have enabled researchers to discover low affinity fragments accurately and understand how they interact with biological targets at atomic level. This has facilitated optimization of hits into potent leads for preclinical testing.
Market Drivers
Increasing prevalence of diseases has necessitated development of novel drugs against difficult biological targets, driving demand for fragment based drug discovery. Additionally, rising R&D expenditure of pharmaceutical companies on drug discovery is also fueling the market growth. Biophysical screening methods integrated with computational capabilities provide faster evaluation of large chemical libraries, augmenting the efficiency of hit identification process.
Current Challenges in the Global Fragment Based Drug Discovery Market
The global fragment based drug discovery market is facing many challenges currently. With the increasing complexity of biological targets, traditional high-throughput screening is yielding lower hit rates. Identifying ligands that bind selectively to targets remains a significant bottleneck in drug discovery. Developing robust screening assays and interpretable biophysical data also poses challenges. The assays need to be sensitive enough to detect weak binding interactions between fragments and targets. Analyzing large datasets generated during screening also requires advanced computational techniques. Integrating fragment screening workflows into existing drug discovery pipelines is another challenge area.
SWOT Analysis
Strength: Fragment based approaches help identify new chemical starting points. They enable exploring vastly larger chemical space compared to traditional high-throughput screening.
Weakness: Developing fragments into drug-like lead molecules requires extra medicinal chemistry efforts. Biophysical techniques used in screening like NMR spectroscopy have limitations in throughput.
Opportunity: Advances in biophysics, computing and automation are expanding the applications of fragment based methods. They can be applied to challenging targets beyond enzymes.
Threats: High capital investment requirements favor large pharmaceutical companies. Startups may find it difficult to gain footing in this specialty area.
Geographical Regions
In terms of value, the North American region currently accounts for the major share in the global fragment based drug discovery market. This is attributed to extensive R&D activities and presence of key market players in the US and Canada. The European region also has a significant market share owing to government funding and initiatives promoting pre-competitive research.
The Asia Pacific region is expected to be the fastest growing market over the forecast period. This is due to increasing government and private investments in drug discovery and biotechnology sectors across China, India, Japan and other Asian countries. Establishing local operations of global pharma companies is additionally fueling market growth.
Get this Report in Japanese Language: 世界のフラグメントベース創薬市場
Get this Report in Korean Language: 글로벌 단편 기반 약물 발견 시장
Explore More Related Topics On -Global Ultrasonic Nebulizer Industry - An Overview
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
